GENT logo

Gentian Diagnostics ASA Stock Price

OB:GENT Community·NOK 564.2m Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 3 Fair Values set on narratives written by author

GENT Share Price Performance

NOK 36.50
36.50 (0.00%)
NOK 60.00
Fair Value
NOK 36.50
36.50 (0.00%)
39.2% undervalued intrinsic discount
NOK 60.00
Fair Value
Price NOK 36.50
AnalystConsensusTarget NOK 60.00

GENT Community Narratives

·
Fair Value NOK 60 39.2% undervalued intrinsic discount

Expanding Into $18 Billion Diagnostics Market Will Boost Prospects Despite Potential Risks

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative

Trending Discussion

Updated Narratives

GENT logo

GENT: Pipeline Reallocation And Share Mandate Will Support Future Upside

Fair Value: NOK 60 39.2% undervalued intrinsic discount
3 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet with high growth potential.

1 Risk
2 Rewards

Gentian Diagnostics ASA Key Details

NOK 175.9m

Revenue

NOK 83.0m

Cost of Revenue

NOK 92.9m

Gross Profit

NOK 107.7m

Other Expenses

-NOK 14.8m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Jul 09, 2026
-0.96
52.80%
-8.41%
0%
View Full Analysis

About GENT

Founded
2001
Employees
64
CEO
Matti Heinonen
WebsiteView website
www.gentian.com

Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. It offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Calprotectin Immunoassay, a turbidimetric assay used for the measurement of circulating calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a GFR marker for the diagnosis and therapeutic control of renal function and chronic kidney disease; Gentian Retinol-Binding Protein Immunoassay for detection of retinol-binding protein in human serum and plasma; and Canine CRP Immunoassay test kit, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine C-reactive protein in dog plasma and serum. The company also develops faecal calprotectin immunoassay turbo that offers results of calprotectin concentration in stool supporting diagnosis of inflammatory bowel disease; and faecal pancreatic elastase immunoassay turbo, which allows analysis of pancreatic elastase in stool to aid in diagnosis of pancreatic exocrine insufficiency. Gentian Diagnostics ASA was founded in 2001 and is headquartered in Moss, Norway.

Recent GENT News & Updates

Narrative Update May 12

GENT: Share Issue Mandate And Dividend Policy Will Support Future Upside

Analysts have adjusted their price target for Gentian Diagnostics from NOK 67 to NOK 60. They point to updated assumptions for revenue growth, profit margins and future P/E that they see as better reflecting the company’s current risk profile and earnings potential.

Recent updates

No updates